Cargando…

From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies

Current cell-based therapies to treat degenerative diseases such as osteoarthritis (OA) fail to offer long-term beneficial effects. The therapeutic effects provided by mesenchymal stem cell (MSC) injection, characterized by reduced pain and an improved functional activity in patients with knee OA, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Laplace-Builhé, Béryl, Bahraoui, Sarah, Jorgensen, Christian, Djouad, Farida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873919/
https://www.ncbi.nlm.nih.gov/pubmed/33585444
http://dx.doi.org/10.3389/fcell.2020.605120
_version_ 1783649476737499136
author Laplace-Builhé, Béryl
Bahraoui, Sarah
Jorgensen, Christian
Djouad, Farida
author_facet Laplace-Builhé, Béryl
Bahraoui, Sarah
Jorgensen, Christian
Djouad, Farida
author_sort Laplace-Builhé, Béryl
collection PubMed
description Current cell-based therapies to treat degenerative diseases such as osteoarthritis (OA) fail to offer long-term beneficial effects. The therapeutic effects provided by mesenchymal stem cell (MSC) injection, characterized by reduced pain and an improved functional activity in patients with knee OA, are reported at short-term follow-up since the improved outcomes plateau or, even worse, decline several months after MSC administration. This review tackles the limitations of MSC-based therapy for degenerative diseases and highlights the lessons learned from regenerative species to comprehend the coordination of molecular and cellular events critical for complex regeneration processes. We discuss how MSC injection generates a positive cascade of events resulting in a long-lasting systemic immune regulation with limited beneficial effects on tissue regeneration while in regenerative species fine-tuned inflammation is required for progenitor cell proliferation, differentiation, and regeneration. Finally, we stress the direct or indirect involvement of neural crest derived cells (NCC) in most if not all adult regenerative models studied so far. This review underlines the regenerative potential of NCC and the limitations of MSC-based therapy to open new avenues for the treatment of degenerative diseases such as OA.
format Online
Article
Text
id pubmed-7873919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78739192021-02-11 From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies Laplace-Builhé, Béryl Bahraoui, Sarah Jorgensen, Christian Djouad, Farida Front Cell Dev Biol Cell and Developmental Biology Current cell-based therapies to treat degenerative diseases such as osteoarthritis (OA) fail to offer long-term beneficial effects. The therapeutic effects provided by mesenchymal stem cell (MSC) injection, characterized by reduced pain and an improved functional activity in patients with knee OA, are reported at short-term follow-up since the improved outcomes plateau or, even worse, decline several months after MSC administration. This review tackles the limitations of MSC-based therapy for degenerative diseases and highlights the lessons learned from regenerative species to comprehend the coordination of molecular and cellular events critical for complex regeneration processes. We discuss how MSC injection generates a positive cascade of events resulting in a long-lasting systemic immune regulation with limited beneficial effects on tissue regeneration while in regenerative species fine-tuned inflammation is required for progenitor cell proliferation, differentiation, and regeneration. Finally, we stress the direct or indirect involvement of neural crest derived cells (NCC) in most if not all adult regenerative models studied so far. This review underlines the regenerative potential of NCC and the limitations of MSC-based therapy to open new avenues for the treatment of degenerative diseases such as OA. Frontiers Media S.A. 2021-01-21 /pmc/articles/PMC7873919/ /pubmed/33585444 http://dx.doi.org/10.3389/fcell.2020.605120 Text en Copyright © 2021 Laplace-Builhé, Bahraoui, Jorgensen and Djouad. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Laplace-Builhé, Béryl
Bahraoui, Sarah
Jorgensen, Christian
Djouad, Farida
From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title_full From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title_fullStr From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title_full_unstemmed From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title_short From the Basis of Epimorphic Regeneration to Enhanced Regenerative Therapies
title_sort from the basis of epimorphic regeneration to enhanced regenerative therapies
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873919/
https://www.ncbi.nlm.nih.gov/pubmed/33585444
http://dx.doi.org/10.3389/fcell.2020.605120
work_keys_str_mv AT laplacebuilheberyl fromthebasisofepimorphicregenerationtoenhancedregenerativetherapies
AT bahraouisarah fromthebasisofepimorphicregenerationtoenhancedregenerativetherapies
AT jorgensenchristian fromthebasisofepimorphicregenerationtoenhancedregenerativetherapies
AT djouadfarida fromthebasisofepimorphicregenerationtoenhancedregenerativetherapies